Valeant Pharmaceuticals International, Inc. reached agreement on terms of a revised North American aesthetics arrangement with Galderma S.A. Under the terms, Galderma will continue to supply Restylane and Perlane to Valeant, under the terms and conditions Galderma currently supplies those products to Medicis Pharmaceutical Corporation. In addition, Valeant will make an upfront payment and a royalty to Galderma on sales of Sculptra. In addition, Valeant will obtain North American rights to Emervel, a family of hyaluronic acid dermal fillers. The terms of the agreement are subject to the closing of Valeant's pending acquisition of Medicis, which is expected to occur on December 11, 2012.